Arrowhead Pharmaceuticals Inc (FRA:HDP1)
€ 24.66 4.54 (22.56%) Market Cap: 3.08 Bil Enterprise Value: 2.92 Bil PE Ratio: 0 PB Ratio: 17.54 GF Score: 48/100

Arrowhead Pharmaceuticals Inc at Morgan Stanley Global Healthcare Conference Transcript

Sep 13, 2023 / 04:15PM GMT
Release Date Price: €26.85 (-0.63%)
Michael Eric Ulz
Morgan Stanley, Research Division - Equity Analyst

Good afternoon, everyone, and thanks for joining us at the Morgan Stanley Global Healthcare Conference. I'm Michael Ulz, one of the biotech analysts here. And it's my pleasure to introduce Vince Anzalone, VP of Finance and Investor Relations. Just a reminder, the format for today is a fireside chat. Before we get started, I just need to read a quick disclosure.

For important disclosures, please see the Morgan Stanley research disclosure website at www.morganstanley.com/researchdisclosures. If you have any questions, please reach out to your Morgan Stanley sales representatives. With that, Vince, thanks for joining us today, and maybe I'll just hand it over to you to make some brief intro comments on Arrowhead.

Vincent Anzalone
Arrowhead Pharmaceuticals, Inc. - Head of IR & VP

Sure. Thanks, Mike, and thank you to all of Morgan Stanley for having us today. So Arrowhead Pharmaceuticals, we're

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot